IDOSE TR Drug Patent Profile
✉ Email this page to a colleague
When do Idose Tr patents expire, and when can generic versions of Idose Tr launch?
Idose Tr is a drug marketed by Glaukos and is included in one NDA. There are two patents protecting this drug.
This drug has fifty patent family members in seven countries.
The generic ingredient in IDOSE TR is travoprost. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the travoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Idose Tr
A generic version of IDOSE TR was approved as travoprost by CHARTWELL RX on March 1st, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IDOSE TR?
- What are the global sales for IDOSE TR?
- What is Average Wholesale Price for IDOSE TR?
Summary for IDOSE TR
| International Patents: | 50 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 3,814 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for IDOSE TR |
| What excipients (inactive ingredients) are in IDOSE TR? | IDOSE TR excipients list |
| DailyMed Link: | IDOSE TR at DailyMed |
Pharmacology for IDOSE TR
| Drug Class | Prostaglandin Analog |
US Patents and Regulatory Information for IDOSE TR
IDOSE TR is protected by two US patents and one FDA Regulatory Exclusivity.
Patents protecting IDOSE TR
Implants with controlled drug delivery features and methods of using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Implants with controlled drug delivery features and methods of using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting IDOSE TR
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaukos | IDOSE TR | travoprost | IMPLANT;INTRACAMERAL | 218010-001 | Dec 13, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Glaukos | IDOSE TR | travoprost | IMPLANT;INTRACAMERAL | 218010-001 | Dec 13, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Glaukos | IDOSE TR | travoprost | IMPLANT;INTRACAMERAL | 218010-001 | Dec 13, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for IDOSE TR
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Izba | travoprost | EMEA/H/C/002738 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma. |
Authorised | no | no | no | 2014-02-20 | |
| Novartis Europharm Limited | Travatan | travoprost | EMEA/H/C/000390 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1). |
Authorised | no | no | no | 2001-11-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for IDOSE TR
See the table below for patents covering IDOSE TR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014348667 | Ocular implants configured to store and release stable drug formulations | ⤷ Sign Up |
| Japan | 6842484 | ⤷ Sign Up | |
| Japan | 6491636 | ⤷ Sign Up | |
| Australia | 2018229507 | Drug eluting ocular implant | ⤷ Sign Up |
| Australia | 2019201946 | Implants with controlled drug delivery features and methods of using same | ⤷ Sign Up |
| Australia | 2023270343 | Implants with controlled drug delivery features and methods of using same | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IDOSE TR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1920764 | C01920764/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002 |
| 1920764 | C300540 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127 |
| 1920764 | PA2012017,C1920764 | Lithuania | ⤷ Sign Up | PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127 |
| 1920764 | 2012/033 | Ireland | ⤷ Sign Up | PRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN |
| 1920764 | 1290027-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: TRAVOPROST |
| 1514548 | C300671 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
